BioLife Solutions, Inc.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services used in research and commercial manufacturing of biologic-based therapies, particularly cell and gene therapies. Its products support the preservation, processing, and thawing of biological materials used by therapy… From the company’s description.
Over the twelve months to Jun 30, 2026, BioLife Solutions, Inc. reported revenue of $102.82M and net income of $57.98M. Its operating margin was 2.9%, and operations generated $16.88M in cash. In fiscal 2025, it reported revenue of $96.21M and a net loss of $4.59M.
Dotted labels explain each measure. is shown separately from the annual figures.
What BioLife Solutions, Inc. does
In the company’s own words
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services used in research and commercial manufacturing of biologic-based therapies, particularly cell and gene therapies. Its products support the preservation, processing, and thawing of biological materials used by therapy developers and manufacturers. BioLife operates as one bioproduction business, with offerings that include biopreservation media, human platelet lysate media, cell-processing containers and fill machines, and automated thawing devices. Its CryoStor and HypoThermosol FRS media are formulated to preserve cells and tissues at low temperatures; other brands include CellSeal, CryoCase, ThawSTAR, and Stemulate. The company’s products are sold through direct sales and third-party distributors. In 2025, revenue is concentrated in CryoStor products, which account for approximately 82% of revenue, and customers are located primarily in the United States. BioLife had 155 full-time team members as of December 31, 2025. It acquired the remaining interest in PanTHERA CryoSolutions in 2025, adding cryopreservation technology, and divested several storage, logistics, freezer, and shipping businesses in 2024 and 2025. Its website is www.biolifesolutions.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Electromedical Apparatus
- Headquarters
- BOTHELL, WA
- Fiscal year end
- December
- CIK
- 834365
- SIC
- 3845
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BioLife Solutions, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BioLife Solutions, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BioLife Solutions, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BioLife Solutions, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BioLife Solutions, Inc.'s last four quarterly filings that the numbers alone won't show?”